• Pin-Ko Chen, Sung-Hua Chiu, Ming-Ting Tsai, Kai-Hsiang Chang, Wei-Chou Chang, Hsuan-Hwai Lin, Cheng-Hsiang Lo, Guo-Shu Huang, and Ping-Ying Chang.
• Department of Radiology, Tri-Service General Hospital, National Defense Medical Center, Taipei, ROC, Taiwan.
• J Chin Med Assoc. 2022 Apr 1; 85 (4): 491499491-499.

BackgroundTo compare the efficacy and safety of combination therapy with sorafenib and drug-eluting bead transarterial chemoembolization (DEB-TACE) in advanced hepatocellular carcinoma (HCC) with or without hepatic arteriovenous shunt (HAVS).MethodsThis retrospective, single-center study enrolled 59 advanced HCC patients treated with combination therapy, of whom 33 (55.9%) patients had HAVS. Tumor response according to the mRECIST criteria was evaluated based on the CT images 1 month after TACE, and changes in the arterial enhancement ratio (AER) of tumors and portal vein tumor thrombosis were also documented. Time-to-progression (TTP), overall survival (OS), and prognostic factors were analyzed. Safety was evaluated with the incidence of TACE-related complications within 6 weeks after TACE.ResultsThe tumor response between the two groups showed no significant difference in the objective response rate (69.2% in the group without HAVS vs 60.6% in the group with HAVS, p = 0.492) or disease control rate (92.3% vs 87.9%, p = 0.685). The two groups showed comparable TTP (4.23 vs 2.33 months, p = 0.235) and OS (12.77 vs 12.97 months, p = 0.910). A drop in the AER of tumors of more than 20% on post-TACE CT independently predicted better OS. With regard to safety, there was no significant difference between the two groups.ConclusionFor advanced HCC, combination therapy had equal efficacy and safety in patients with HAVS compared to those without HAVS, indicating that DEB-TACE is an optional and effective treatment in these patients.Copyright © 2022, the Chinese Medical Association.

12 keywords...

hide…